Abstract
Introduction:
Despite recent advancements, certain hard to treat cancers such as brain, pancreatic and triple negative breast cancer (TNBC) still have a poor prognosis. Therapy resistance is one of the major contributing factors to the failure of cancer therapy, leading to relapse, metastasis and mortality. Radio- and chemoresistance can occur for a variety of reasons. One of the major contributing factors to therapy resistance is tumour heterogeneity. Thus, during treatment cancer cells continue to evolve and mutate often to therapy resistant phenotypes. Over the course of the disease and its treatment, cancers become more heterogeneous and are composed of pockets of tumour cells which are molecularly distinct from others and possess differential levels of sensitivity to therapies. As a result of this, many current cancer therapies have limited success and more optimal combination chemoradiotherapies are needed.
Material and Methods:
TNBC cells were cultured in 2D and 3D models to investigate the efficacy of combination therapies designed from chemotherapy or irradiation and a pre-approved Drug X. Drug X has been shown to inhibit the NRF2 pathway and is currently used as a treatment for several autoimmune diseases. TNBC cells resistant to radiation and chemotherapy, developed in house by serial culture were used to investigate novel combination therapies to overcome resistance. Clonogenic assays and 3D spheroids were used to investigate toxicity and mechanistic studies such as comet assay & cell cycle analysis to understand the mechanisms underpinning observed effects.
Results and Discussions:
Specifically scheduled combination therapies using chemotherapy and radiation with Drug X in toxicity studies, showed a statistically significantly reduction in survival when compared with the control and the individual treatments alone. Mechanistic studies suggest an increase in DNA damage, depletion in glutathione levels and cell cycle arrest between combination therapy, control and single treatments. These findings in TNBC cells were mirrored in the resistant cells, providing a possible combination therapy that can be used to overcome resistance in TNBC patients.
Conclusion:
Our research focuses on utilising medicines already approved for other conditions and using them in combination with current therapies to improve the efficacy of the treatment and potentially reduce the amount of chemotherapy/radiotherapy required. The results found provide a promising potential treatment option for TNBC patients with recurring cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 422-422 |
| Number of pages | 1 |
| Journal | Molecular Oncology |
| Volume | 17 |
| Issue number | S1 |
| DOIs | |
| Publication status | Published - 8 Jun 2023 |
| Event | EACR 2023 Congress: Innovative Cancer Science - Italy, Turin, Italy Duration: 12 Jun 2023 → 15 Jun 2023 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- drug repurposing
Fingerprint
Dive into the research topics of 'Repurposing drugs for the development of novel combination therapies for the treatment of cancers'. Together they form a unique fingerprint.Student theses
-
The development of novel combinations therapies for the treatment of triple negative breast cancer
Gardiner, H. (Author), Boyd, M. (Supervisor) & Mullen, A. (Supervisor), 20 Mar 2024Student thesis: Doctoral Thesis
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver